Biotechnology

AsymBio to secure $184m to support growth in biologics manufacturing

Biologics contract development and manufacturing organisation (CDMO) AsymBio is set to secure 1.2397bn yuan (approximately $184m) from Asymchem Group, Hillhouse Qirui and other investors to support its long-term growth.

Phylo and Chugai collaborate to deploy AI platform in drug discovery

Phylo has entered a collaboration with Japan-based company Chugai Pharmaceutical to implement Biomni Lab, an agentic AI platform designed for biomedical research, within the latter’s drug discovery operations.

Ratio Therapeutics secures $70m Series C funding for cancer radiotherapy

Ratio Therapeutics, a US-based clinical-stage developer of radiopharmaceuticals for cancer treatment, has closed a $70m Series C financing round.

miRecule and Rio Biofarma to develop RNA therapeutic delivery technologies

miRecule has signed a research collaboration with EM subsidiary Rio Biofarma Brasil (RBBL) to co-develop peptide-mediated delivery technologies aimed at improving targeted ribonucleic acid (RNA) therapeutics delivery to tissues beyond the liver and muscles in a range of disease areas.

BioMarin and n-Lorem partner on early research for ReNU syndrome therapy

BioMarin Pharmaceutical and n-Lorem Foundation have entered an early-stage research collaboration and exclusive global licence agreement to develop an investigational antisense oligonucleotide (ASO) therapy for ReNU syndrome.

argenx signs agreement to buy Forte Biosciences for $2.2bn

argenx has entered a definitive agreement to acquire Forte Biosciences for approximately $2.2bn in total equity value.

Biointron introduces RushData platform for AI-driven antibody discovery

Biointron Biological has launched RushData, a new platform to support the process of antibody discovery for pharmaceutical and biotechnology companies employing AI and machine learning (ML).

Evogene and ELEO to develop new oral PCSK9 inhibitors

Evogene and ELEO have entered a scientific collaboration aimed at discovering and developing new oral small-molecule inhibitors targeting the Proprotein convertase subtilisin/kexin type 9 (PCSK9) pathway for hyperlipidemia and cardiovascular diseases.

Cellares and Papillon partner for PPL-001 manufacturing automation

Cellares and Papillon Therapeutics have entered a partnership to automate the manufacturing of PPL-001, an investigational therapy developed by the latter for Friedreich’s ataxia (FA), a rare inherited neurodegenerative disorder.